Quanterix Corporation · NASDAQ:QTRX
Quanterix — Barclays Global Healthcare Conference 2023
30 slides from Quanterix's conference presentation, 2023
Slide 1: Barclays Global Healthcare Conference 2023
„ 2023 Barclays Global Healthcare Conference Masoud Toloue CEO, Quanterix
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expression
Slide 3: Ultrasensitive biomarker detection to transform the future of healthcare
OUR MISSION Ultrasensitive biomarker detection to transform the future of healthcare (1) INSTRUMENTS ACCELERATOR Placements (2) Projects (2) GEOGRAPHY CUSTOMER NA 60% Academia 55% BIOMARKERS PUBLICATIONS Europe 30% Pharma / CROs 45% Cumulative (2) Cumulative (2) Asia 10% (1) FY2022 actuals $105.5M (
Slide 4: Key Messages
Key Messages Our unmatched Simoa technology is a key competitive advantage for continued market leadership We are early in penetration of a $75B discovery to diagnostics proteomics market opportunity Our strategy is to deliver novel biomarker detection to unlock proteomics research and translate tho
Slide 5: Single Molecule Array Technology (Simoa)
Single Molecule Array Technology (Simoa) Analog Digital Traditional ELISA assay Millions of molecules needed to reach detection limit SUBSTRATE 0 pM 10 pM 0 aM 3.5 aM 350 aM 3.5 fM 5
Slide 6: Proteome is dynamic and closest to clinical actionability
Proteome is dynamic and closest to clinical actionability Simoa sensitivity allows digital detection of proteins and their isoforms PROTEIN 1M+ Protein isoforms 20,000 200,000 genes RNA transcripts Simoa sensitivity enables… Less invasive, smaller sample New biomarkers & protein isoforms Multiplexin
Slide 7: Our sensitivity enables discovery and Dx
ELISA ng/mL Democratize SIMOA; one in every research lab Our sensitivity Other protein pg/mL detection 900x Sensitivity technology enables discovery increase fg/mL Simoa Today and Dx Early disease Simoa innovation detection 7
Slide 8: Transforming Medicine with Digital Biomarkers
Simoa Technology Transforming Medicine with Digital Biomarkers H E A LT H Y S TAG E O F I N T E R V E N T I O N L AT E D I S E A S E Non-invasive Invasive Blood-based Simoa Neuro Assays CSF & PET Imaging 8
Slide 9: Proteomics Value Chain
Proteomics Value Chain Plexity Plexity Plexity Plexity 100+ 1-50 1-10 1-3 • Relevant • Early Detection • Home, less invasive • Early Detection Proteins • Multiplex • Early Detection • Quantitative / Precise • Quantitative / Precise • Quantitative / Precise • Home, Less Invasive *Source: SVB Leerink
Slide 10: Proteomics Landscape
Discovery Translational Research / Drug Trials Diagnostics • Which markers • Sample in - results out • Multi-site testing • High analytical and automation clinical Sensitivity • High multiplex • Greater sensitivity • Sensitivity to detect early needed in future • High precision • Low sensitivity in
Slide 11: Under penetrated in a large and expanding research market
Under penetrated in a large and expanding research market Blood Vessels Immune System Heart Lungs Digestive System Kidneys Liver Reproductive Organs Systemic Inflammation 6% of NIH budget used to reflect Nuero 11
Slide 12: Simoa; in every research lab
Simoa; in every research lab Therapeutic Area Expansion $20B Proteomics Research Inclusive of all therapeutic areas • Growth into new applications and biomarker assays to capture 90% of research market outside of neurology Neurology Applications Increased Sensitivity $2B <10% of NIH budget and pharm
Slide 13: Upcoming Neuro Decade
Upcoming Neuro Decade Blood based biomarkers ushering in a new generation of neuro health assessment and monitoring FDA approves first Alz Drugs Alz blood Alz drug monitoring based Dx test blood test FDA approval of Tx FDA approval of Alz therapy Anti-Tau FDA for MCI & early Alz cognitively unimpair
Slide 14: Non-invasive Blood-based Simoa Assays
Non-invasive Blood-based Simoa Assays 14
Slide 15: Clinical trial engagement
Clinical trial engagement Non-invasive biomarker measurements empower pre- and post-market clinical trials Donanemab JNJ-6373365 Lecanemab Ranibizumab Patisiran Phase 2 Phase 2 Phase 3 Phase 4 Phase 3 Simoa based Simoa based Simoa pTau181, Simoa based Simoa NfL assay pTau217 pTau217+ GFAP, NfL VEGF
Slide 16: Blood Based Alzheimer's Disease Testing – Game Changer for AD Trials and Treatment
Blood Based Alzheimer's Disease Testing – Game Changer for AD Trials and Treatment Clinical Dementia Diagnosis MCI Preclinical sMRI FPG-PET Simoa pTau Biomarkers Tau-PET Blood Test Aβ-PET Simoa phosphorylated Tau is being used across drug platforms for Tau early detection Pathological Changes Aβ Qua
Slide 17: Simoa p-Tau 181 test; biomarker endpoint on Leqembi label
Simoa p-Tau 181 test; biomarker endpoint on Leqembi label 10 mg/kg Leqembi every two weeks reduced mean plasma pTau-181 24% from baseline in 79 weeks, a highly significant decrease. 10 mg/kg every two weeks Amyloid Beta PET Composite SUVR N=44 N=98 Mean baseline 1.373 1.402 Adjusted mean change from
Slide 18: Alzheimer's treatment workflow
Alzheimer’s treatment workflow Blood biomarkers can streamline clinical workflows and broaden access to treatment Today: Blood biomarkers reduce Confirm amyloid pathology number of un-necessary PET scans Treatment & PET screen Monitoring Blood Referral for Cognitive biomarker memory concerns Assessm
Slide 19: Strength in neurology enables access to large markets
Strength in neurology enables Existing biomarker menu has potential to provide access to large markets TAM $8B TAM $2B TAM $0.5B Triage Diagnosis Monitoring Disease Diagnosis Activity Screening Monitoring Treatment After drug approval* Response Baselining *Future TAM opportunity in neurology 19
Slide 20: NfL CLIA blood test expands access to brain health biomarker
NfL CLIA blood test expands access to brain health biomarker NfL in serum validated as a CLIA Laboratory Developed Test (LDT) (>100 publications) 20
Slide 21: NfL
Driving biomarker discoveries to research, to trials and Dx NfL (>100 publications) 21
Slide 22: Building a menu of blood biomarker LDTs to serve a broader market
Building a menu of blood biomarker LDTs to serve a broader market..... ….....leading conversion of neuro biomarkers into diagnostics LDT Blood-Based Neuro Biomarker Menu Clinical Research Ptau181 CLIA LDT (launched Q3 2022) • Prospective studies • Clinical utility studies NfL CLIA LDT Clinical Care
Slide 23: Corporate Transformation: Progress on Assay Redevelopment Roadmap
Corporate Transformation: Progress on Assay Redevelopment Roadmap Q2 2022 Q3 2022 Q4 2022 H1 2023 H2 2023 CEO transition on Strategic review Stability and variance Manufacturing Process automation April 25th completed in July, improvements for implementation Process scaling business real
Slide 24: 2023 Gross Margin: Two quarters into our transformation
2023 Gross Margin: Two quarters into our transformation to democratize Simoa in research markets and unlock clinical and diagnostic TAM Non-recurring License Fee Products & Projects 41.3% 3.0% 34.9% 3.2% Profitable Growth: 38.3% Expect to end 2023 29.1% with Non-GAAP gross 4.0% 31.7% margin in the l
Slide 25: 2023 Guidance
2023 Guidance Expect modest growth in 2023, as we continue to make progress on our corporate Transformation; return to double digit growth by 2024 (in millions) $105.5 $103 - $109 $5.0 ~$6.0 Non-Recurring License fee $3.0 Cash flow positive Collaboration project Expect to end the year with at $170-$
Slide 26: Leader in proteomics, positioning ourselves to accelerate faster
Leader in proteomics, positioning Most Sensitive Protein ourselves to Measurements in Blood Strong IP protection Adding accelerate faster Accelerants Translational Leader FDA - BTD pTau181, NfL LDT implementation Pharma / KOL partnerships Sample to Answer Platform Rapid TAT, Global footprint New Con
Slide 27: Key take aways
Key take aways Continue to lead by delivering sample to answer product portfolio, uniquely detecting difficult to measure protein isoforms and transforming them into biomarkers. Therapeutic area expansion to provide Simoa sensitivity to all proteomics researchers; until there is at least one platfor
Slide 28: Appendix
Quanterix Discovery Fueled by Ultra-Sensitivity
Slide 29: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Three Months Three Months Ended December Three Months Ended September Year Ended December 31, 31, Ended June 30, 30, 2022 2021 2022 2022 2022 2021 GAAP gros
Slide 30: Condensed Consolidated Statements of Operations
Quanterix Corporation Condensed Consolidated Statements of Operations (Unaudited and in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Product revenue $ 16,674 $ 23,476 $ 69,808 $ 81,062 Service and other revenue 8,767 5,674 34
Quanterix — Barclays Global Healthcare Conference 2023 on 6ix